ERASCA INC. - COMMON STOCK

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

09 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in November

08 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca to Present at the Cantor Global Healthcare Conference

19 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

05 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

29 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

10 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

22 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

05 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

31 May 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

25 May 2023 16:00:00 By Nasdaq GlobeNewswire

Erasca Further Strengthens Business Leadership with Two Key Promotions

16 May 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca Reports First Quarter 2023 Financial Results and Business Updates

15 May 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

02 May 2023 07:00:02 By Nasdaq GlobeNewswire

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

01 May 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

26 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire